Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by Celgene
Information provided by (Responsible Party):
Celgene Identifier:
First received: November 21, 2012
Last updated: May 9, 2017
Last verified: May 2017
This study will enroll approximately 460 subjects, aged 55 or older, with a diagnosis of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved first Complete remission (CR)/ Complete remission with incomplete blood count recovery (CRi) following induction with or without consolidation chemotherapy. Subjects who have previously achieved CR/CRi with a hypomethylating agent will be excluded from the study.

Condition Intervention Phase
Leukemia, Myeloid, Acute
Drug: 300 mg Oral Azacitidine
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Resource links provided by NLM:

Further study details as provided by Celgene:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 60 months ]
    Number of participants who survive

Secondary Outcome Measures:
  • Relapse free survival (RFS) [ Time Frame: 60 months ]
    Number of participants who survive without relapsing

  • Complete Remission (CR)/Complete Remission with incomplete blood count recovery (CRi) [ Time Frame: 60 months ]
    Time to relapse from Complete Remission (CR)/Complete Remission with incomplete blood count recovery (CRi). Time to relapse from CR/CRi is defined as the interval from the date of randomization to the date of documented relapse after CR or CRi, as defined according to the IWG AML response criteria.

  • Safety and Tolerability [ Time Frame: 60 months ]
    Number of participants with adverse events

  • Healthcare Resource Utilization [ Time Frame: 60 months ]
    Effect of oral azacitidine compared with Placebo on healthcare utilization. Healthcare utilization data will be collected as described below: Information on each hospitalization will be collected utilizing a CRF designed specifically for this purpose. Information to be collected will include, but not be limited to, the reason for hospitalization (eg, disease relapse, AML-related illness, treatment-related AE), and days of hospitalization by treatment setting (inpatient, special care unit). Other disease- and treatment-related forms of healthcare utilization will be collected through routine study activities. These include diagnostic procedures and treatment interventions not requiring hospitalization such as those required for AML-related illness, or for treatment-related adverse events. Additionally, information on all concomitant medications and resource use associated with treatment administration for AML will be collected. Healthcare resource utilization information will be

  • Patient-reported outcomes utilizing the FACIT-Fatigue Scale and the EQ-5D [ Time Frame: 60 months ]
    FACT-F Functional Assessment of Cancer Therapy-Fatigue, EuroQol-5D (EQ-5D) measure of health outcome and 3 additional exploratory questions

Estimated Enrollment: 460
Actual Study Start Date: April 24, 2013
Estimated Study Completion Date: April 30, 2019
Estimated Primary Completion Date: January 31, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral Azacitidine
300mg Oral Azacitidine for the first 14 days of each 28 days treatment cycle
Drug: 300 mg Oral Azacitidine
Maintenance therapy
Placebo Comparator: Placebo
300 mg Placebo for the first 14 days of each 28 days treatment cycle
Drug: Placebo

Detailed Description:
This is an international, multicenter, placebo-controlled, phase3 study with a double-blind, randomized, parallel-group design with de novo AML (Acute Myeloid Leukemia) or AML secondary to prior diagnosis of Myelodysplasic Syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects ≥ 55 years of age
  2. Newly diagnosed, histologically confirmed de novo AML or AML secondary to prior myelodysplastic disease or CMML (Chronic myelomonocytic leukemia)
  3. First Complete remission (CR)/ Complete remission with incomplete blood count recovery (CRi) with induction therapy + consolidation therapy within 4 months (+/- 7 days of achieving CR or CRi)
  4. Eastern Cooperative Oncology Group (ECOG) performance status - 0, 1, 2, 3

Exclusion Criteria:

  1. AML with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) or molecular evidence of such translocations
  2. Prior bone marrow or stem cell transplantation
  3. Have achieved CR/CRi following therapy with hypomethylating agents
  4. Diagnosis of malignant disease within the previous 12 months
  5. Proven Central Nervous System (CNS) leukemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01757535

Contact: Andrew Dorman, Study Manager +1 908-673-2076

  Show 220 Study Locations
Sponsors and Collaborators
Study Director: Ignazia La Torre, MD Celgene Corporation
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Celgene Identifier: NCT01757535     History of Changes
Other Study ID Numbers: CC-486-AML-001
2012-003457-28 ( EudraCT Number )
Study First Received: November 21, 2012
Last Updated: May 9, 2017

Keywords provided by Celgene:
Maintenance therapy
Acute Myeloid Leukemia
oral Azacitidine
best supportive care
complete remission

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors processed this record on May 25, 2017